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ABSTRACT 
Objective: The main aim of the present study was development of mucoadhesive insitu gel for transmucosal delivery of celecoxib to increase its 
bioavailability by avoiding first pass metabolism. In the present study, transmucosal route was used for delivery of celecoxib so as to bypass the first 
pass metabolism seen in drug with oral route.  
Methods: Temperature sensitive bio-adhesive in situ gel was prepared for the delivery of celecoxib in the rectal cavity. Optimization of the 
formulation was done using partial factorial (2[4-1]) design considering the concentration all the excipients as independent variables.  
Results: The optimized formulation containing 0.71% polymer, 3.5% NaCl, 9.12% PEG 400, 0.5% sodium lauryl sulfate was found to possess gelling 
temp 38°C, bio adhesion strength 4.05 g/cm2 and 88.39%  in vitro drug release in three hours. Pharmacokinetic study of the optimized batch was 
performed in male Wistar rats. It was found that the bioavailability of in situ formulation was increased by 1.54 folds as compared to that of the 
marketed formulation by same route.  
Conclusion: It was concluded that development of mucoadhesive insitu gel for transmucosal delivery of celecoxib was found to be a promising 
approach to obtain celecoxib drug with increased in the bioavailability of the drug. 
Keywords: Celecoxib, Transmucosal route, In-situ gel, Partial factorial study, Pharmacokinetic study. 
 
INTRODUCTION  
Celecoxib is BCS class2 drug having low solubility, celecoxib is a non 
steroidal anti inflammatory drug and a selective cox-2 inhibitor. It is 
used in treatment of rheumatoid arthritis, acute pain, osteoarthritis, 
painful menstruation, menstrual symptoms, and to reduce number 
of colon and rectum polyps in the people with familial adenomatous 
polyposis. It acts as an anti-inflammatory agent as it inhibits 
prostaglandin synthesis. It has been found that celecoxib drug is 
predominately eliminated by hepatic metabolism with little 
unchanged (< 3%) amount excreted in urine and faces [1- 3].  
Its bioavailability is around 40%, which may be attributed to its 
lower solubility & first pass metabolism. Thus transmucosal route 
was assumed to improve the bioavailability of celecoxib. Mucosal 
surface are generally efficient absorption site because of the absence 
of stratum corneum epidermidis, which are considered to be a major 
barrier for drug absorption. Mucosal surfaces are rich in blood 
supply providing a better chance for the drug to transport in 
systemic circulation and avoiding, in most case, degradation of drug 
by first-pass hepatic metabolism [4-6]. Various routes for 
transmucosal drug delivery system are there which includes the 
following Nasal, buccal, ocular, rectal drug delivery system.[7]In the 
present study, rectal route was preferred because the volume 
required to be administered was higher than the volume that can be 
comfortably administered through other mucosal routes like nasal, 
buccal or ocular. 
Bio adhesive in situ gel was prepared for ease of administration & 
retention at the site of absorption. ‘In situ’ is Latin phrase that means 
‘in position’. In situ forming gels are drug delivery systems which are 
in sol form before administration in the body, after administration in 
the body [7,8].  
Routes of administration include ocular, rectal, oral, vaginal, 
injectable & intraperitoneal. Various biodegradable polymers like 
gellan gum, Alginic acid, xyloglucan, Pectin, Chitosan, Poly (DL-lactic 
acid), poly (DL-lactide-co-glycolide) and poly-caprolactone etc. are 
some of the examples used in the formation of in situ gel[9]. Gelling 
can take place due to pH [10]or change in temperature [11-17]. 
Development of temperature sensitive in situ gel was the aim of the 
present research work.  Ease of administration, reduced dosing 
frequency, improved patient compliance and comfort, simple 
formulation, low manufacturing cost, improved retention at 
absorption site, sustained and controlled release are some of the 
advantages of insitu gelling system.[10] 
MATERIALS AND METHODS 
Materials  
Celecoxib was a gift sample from Alembic Pharmaceuticals limited, 
Vadodara, India. Methyl cellulose was purchased from Aatur Instru 
Chem, Vadodara. Sodium chloride (NaCl), potassium chloride (KCl) and 
sodium bicarbonate (NaHCO3) were purchased from S. D. Fine chemicals, 
Mumbai, India. Sodium lauryl sulfate (SLS), PEG 400 and HPLC grade 
methanol were procured from Loba Chemie, Mumbai, India.  
Selection of ingredients 
Methyl cellulose (MC) was used as the gelling polymer. Effect of 
different salts (NaCl, KCl, NaHCO3) was studied on the gelation 
temperature of MC. As celecoxib has poor solubility in water, 
cosolvent was selected for the formulation out of ethanol, glycerine, 
propylene glycol & PEG400 by saturation solubility study. Surfactant 
SLS was also used to increase the wet-ability and reduce coarse 
precipitation of celecoxib.  
Preparation of the formulation  
The in-situ gel formulations were prepared by simple mixing of drug 
solution in polymer solution. [12-16]Briefly, weighed quantity of 
polymer, surfactant and salt were dissolved in water in one beaker. 
In another beaker drug was dissolved in PEG 400. The drug solution 
was added to the polymer solution with continuous stirring using 
magnetic stirrer for 30 minutes at 150-200 rpm.  
Optimization of formulation 
Gelling capacity (gelling time, gelling temperature), bio adhesion 
strength, viscosity, In vitro drug release were selected as dependent 
variables for the optimization study. Various independent variables 
selected were conc. of polymer (methyl cellulose), conc. of surfactant 
(SLS), conc. of PEG 400, conc. of salt (NaCl). Fractional factorial 
design of 2[4-1] was used for the optimization of concentrations of all 
these 4 variables on the formulation. In the fractional factorial 
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design four factors were used and evaluated each at two levels and 
performing the experimental trials at all the eight possible 
combinations.  
The model matrix design layout for 2[4-1] for fractional factorial 
design was developed according to Gareth [18]. Compositions of all 
the formulations are given in Table 1. 
 
Table 1: Compositions of Formulations F1-F8 
Batches no Drug (mg) Methyl cellulose (mg) PEG 400 (ml) Sodium chloride (mg) SLS (mg) Water (q. s. ml) 
F1 750 75 0.75 370 75 15 
F2 750 225 1.5 370 75 15 
F3 750 225 0.75 520 75 15 
F4 750 75 1.5 520 75 15 
F5 750 225 0.75 370 150 15 
F6 750 75 1.5 370 150 15 
F7 750 75 0.75 520 150 15 
F8 750 75 1.5 520 150 15 
 
Evaluation parameters of in situ gel formulation  
Rheological property (viscosity)  
In rheological studies, viscosity determination of sample was done 
using Brookfield (DVLV-I+ PRO) prime model viscometer using 
spindle no 62. At angular velocity of 30 rpm and constant 
temperature (37±1°C), viscosity of all the formulations were 
measured. The average of three readings was used for determining 
the viscosity. Viscosity of the formulations were measured at two 
points before gelling and after gelling[12]. 
Gelling Capacity 
Gelling temperature  
The prepared formulation was taken in transparent glass vial. It was 
kept in a water bath maintained at constant temperature (starting at 
30 + 2°C). The glass vials were inverted and visually evaluated. If not 
gelled, the temperature of the water-bath was gradually increased 
till the sample started gelling[13]. 
Gelling time  
The gelling time of the formulations were determined by taking 2 ml 
of the formulation into a glass vial, which was placed in the water 
bath maintained at temperature 37+2°C. The time taken for gel 
formation was noted[13]. 
Gel strength 
Gel strength was performed by noting down the time up to which it 
remains in the form of gel at constant temperature of (37+2°C) using 
water bath. [13] 
Drug content  
Drug content was determined by dissolving 1 ml of formulation in 
methanol by shaking for few minutes. The concentration of celecoxib 
was determined at 248.5 λmax using UV spectrophotometer after suitable 
dilution against blank formulation treated in same manner[12-15]. 
Bioadhesive strength 
The bioadhesive strength was measured using a modified two arm 
balance with slight modification. [14-16] The biological membrane 
was fixed to the outer surface of the bottom of a 50 ml beaker with 
cynoacrylate adhesive and then placed in a 100 ml beaker. 
Accurately measured 1 ml formulation was converted into gel by 
exposing it to gelling temperature. The formed gel was transferred 
between the bottom of modified stainless steel pan and beaker. 
Initially, 50 gram preload was applied for the establishment of 
adhesion between gel and biological membrane. For all the 
formulations, preload time was kept constant. At the end of preload time 
another beaker was placed on the opposite pan. Water was added 
further drop by drop into the beaker until the membrane gets detached 
at the opposite end. The weight or mass in grams required to detach the 
pan from membrane gives the measure of bio-adhesive strength.  
In vitro diffusion study 
In vitro diffusion study was performed using USP paddle II at 100 
rpm, using 500 ml of Phosphate buffer pH 7.4 as the dissolution 
medium [12-14] and temperature was maintained at (37±1° C) 
throughout the study. In-situ gel formulation containing was 
inserted into dialysis bag. Both the sides of the dialysis bag were 
sealed to prevent leakage. The dialysis bag was then tied to the 
paddle, such that it remains immersed in the dissolution medium 
during the study. 
Release kinetics 
The drug release data obtained were fitted to zero order, first order, 
Higuchi and Korsemeyer Peppas, Hixson– Crowell model to 
determine the mechanism and corresponding release rate from the 
in situ gel formulation. [14] 
Ex-vivo permeation study 
Ex-vivo permeation study was done in Franz diffusion cell at 100 
rpm at temp (37±1°C) using 40 ml of saline phosphate buffer as 
dissolution media.[15, 16] Buccal mucosa of goat was used as barrier 
membrane for the permeation study. The mucosa was stored 
overnight in saline phosphate buffer pH 7.4. The formulation (2 ml) 
was taken in donor compartment and 1 ml of sample was withdrawn 
at regular time interval and absorbance was measured at 248.5 λmax.  
In vivo pharmacokinetic study  
The In vivo pharmacokinetic study was carried out as per the 
guidelines compiled by the CPCSEA, Ministry of culture, Government 
of India (vide approval to protocol PIPH 30/13 by CPCSEA 
921/AC/05/CPCSEA). Eighteen male Wistar rats weighing 250±10 
gm were used for the bioavailability study. The rats were divided 
into 3 groups containing 6 animals in each group. In first group 6 
animals were given normal saline, second group was given in situ gel 
formulation, and last group was administered with marketed 
formulation (converted into suspension of equivalent strength). 
During the experiment, the animals were anesthetized using diethyl 
ether orally before rectal administration of the formulation. On 
experiment day animals were kept in metabolic cage and dose of 
10mg/kg was given rectally (n=8) in animal using Reyls tube. 
Animals were anaesthetized at time of blood collection from the 
retro orbital plexus using glass capillary. Control groups of rats were 
administered with normal saline. [19-21] 
The collected animal blood samples were analysed by using Bio-
analytical method at regular time intervals for time period of 8 
hours. The blood samples were taken in micro centrifuge tube, in 
that 8 mg of EDTA was added as anticoagulant to prevent blood 
clotting. Collected blood samples were centrifuge in refrigerated 
centrifuge for separation of plasma from the blood. Separated 
plasma (500 µl) was collected through micropipette and 1.5 ml of 
methanol was added and mixed properly so that protein gets 
precipitated. The mixture was centrifuged at 5000 rpm for 20 min. 
After centrifugation supernatant was collected and analyzed by UV 
for determination of drug concentration. [19-21] Prior to sample 
analysis, a standard curve was prepared between 0.2-1.0 µg/ml by 
spiking plasma with known concentration of celecoxib.  
Obtained plasma conc. was plotted against time. The maximum 
plasma concentration (Cmax) and time of peak concentration (Tmax) 
were directly determined from their respective plasma 
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concentration time profile. Non-compartment model was used for 
calculation of different pharmacokinetic parameters. Trapezoidal 
method was used to calculate the concentration time curve i. e. area 
under curve (AUC 0-t). [19]The total area under curve (AUC0-t) was 
calculated by:  
 
AUC 0 − t =  1/2 × (C1 + C2) (t2 − t1) 
 
Relative bioavailability (Fr) was calculated with reference to oral 
suspension using formula the relative bioavailability (Fr) at the 
same dose was calculated as  
 
Fr =
AUC insitu gel 0 − t
AUC marketed formulation0 − t
 
 
RESULTS AND DISCUSSION 
Temperature sensitive in-situ gel for drug delivery have been 
reported to be formed using polymers like Pluronic F68 [11, 12] or 
derived chitosan [13]. Methyl cellulose was selected as the polymer 
as it is widely available semi-synthetic polymer. Though methyl 
cellulose has a gelation temperature above 70°C, its gelling 
temperature can be modified using salts [22-24].  
Selection of ingredients 
In the screening studies carried out for selection of salt, NaCl was 
found to have reduced the gelling temperature of MC nearest to body 
temperature (Table 2). 
 
Table 2: Effect of different salts on gelling temperature of MC 
Batches 
no. 
Conc. of methyl 
cellulose (%) 




M8 1% NaCl (3%) 37 °C 
M9 1% KCl (4%) 40 °C 
M10 1% NaHCO3 
(6%) 
39 °C 
M11 0.5% NaCl (3%) 39 °C 
M12 0.5% KCl (4%) 42 °C 
M13 0.5% NaHCO3 
(6%) 
40 °C 
The solubility of celecoxib was checked in different solvent. Among 
these different solvents, solubility of celecoxib was found to be 
maximum in PEG 400. Thus PEG 400 was selected as co solvent to 
enhance the solubility of drug. In the screening study Effect of 
different conc. of co-solvent (PEG 400) on the gelling temperature of 
the polymer with milliequivalents (0.0595) 3% NaCl salt was 
studied. Significant effect of different conc. of PEG 400 with same 
salt was observed on the gelling temperature of polymer (Table 3). 
Thus, 10% PEG 400 was used as co-solvent. 
 
Table 3: Effect of co-solvent on gelling temp of MC-salt mixture 
B. No. MC (%) Conc. of PEG 400 Gelling temperature 
A1 0.5% 10% 41°C 
A2 0.5% 5% 39 °C 
A3 1% 10% 38°C 
A4 1% 5% 36°C 
A5 1.5 % 10% 38°C 
A6 1.5% 5% 33°C 
* 3% NaCl in each formulation 
 
Optimization study 
For an in situ gel preparation, Gelling capacity (gelling time, gelling 
temperature), bio-adhesion strength, viscosity, and In vitro drug release 
are critical quality attributes. So, these were selected as dependent 
variables. These variables were dependent upon the concentration of 
various ingredients such as polymer (methyl cellulose), salt (NaCl), 
surfactant (SLS), and co-solvent (PEG 400). Hence, they were selected as 
independent variables due to their significant effect on formulation. 
Since the number of independent factors is 4, only 2 levels were selected 
for optimization study. However, the full factorial design 24 gives rise to 
requirement of 16 batches. In order to reduce the requirements of 
experimental batches, fractional factorial design (2[4-1]) was used. In 
the fractional factorial design 4 factors were used and evaluated each at 
2 levels and performing the experimental trials at all the 8 possible 
combinations.  
Rheological properties 
The viscosity of all the formulations from F1 to F8 were measured at 
angular velocity of 20 RPM using spindle no 62 at constant 
temperature (Table 4). 
  
Table 4: Viscosity of formulations at room temperature before and after gelling 
Formulation batches Viscosity in cps (n=3) ± S. D before gelling at 25ºC Viscosity in cps (n=3) ± S.(D after gelling at 37ºC 
F1 95±1.58 945±2.0 
F2 232±2.78 3006±3.04 
F3 201±2.51 2875.1±2.56 
F4 103±1.52 1284±2.64 
F5 212±2.51 2586±2.51 
F6 86.5±2.08 645±1.18 
F7 62.8±2.25 322±2.21 
F8 202±1.52 2385±2.08 
ANOVA (Table 5) using DOE software suggested following equation for viscosity:  
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.  '()! − .  ∗ .  "*((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Table 5: ANOVA table for viscosity 
Source Sum of Squares Df Mean Square F Value p-value Prob> F  
Model 8.008 4 2.002 67.49 0.0029 Significant 
Conc. of methyl cellulose 7.377 1 7.377 248.70 0.0006  
Conc. of 
PEG400 
40171.95 1 40171.95 1.35 0.3287  
Conc. .of salt 14356.65 1 14356.65 0.48 0.5367  
Conc. of surfactant 5.768 1 5.768 19.45 0.0216  
Residual 88986.10 3 29662.03    
Cor Total 8.09 7     
 
It was found that conc. of polymer and conc. of surfactant have P value 0.0006 and 0.0216, respectively (i. e. p<0.05), which gives indication that 
there is significant effect of conc. of polymer and conc. of surfactant on viscosity of the formulation. Therefore, by eliminating non-significant terms, 
the reduced equation become. 
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The positive value of coefficient indicates that viscosity of the 
formulation increases with increase in the concentration of methyl 
cellulose.  
Whereas, with the increase in surfactant-conc., viscosity of the 
formulation decreases.  
Gelling temperature  
Gelling temperature of all the formulations was between 34-43°C 
(Table 6).  
The polynomial equation obtained from the model was  
&!!+ 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(°C) (mean±S. D, n=3) 
Bioadhesion strength 
(g/cm2) ±S. D (n=3) 
F1 37±1.0 4.7±1.2 
F2 36±2.2 5.8±2.2 
F3 34±1.5 6.5±2.3 
F4 39±2.5 4.3±1.0 
F5 38±2.0 5.58±1.2 
F6 43±2.1 2.14±3.1 
F7 40±1.8 2.91±2.9 
F8 38±1.1 5.12±1.2 
The statistical study of the data of response gelling temperature was 
analyzed by design expert and DOE software 9.0. Result of the 
ANOVA (Table 7) was obtained using DOE software  
 
Table 7: ANOVA table for gelling temperature 
Source Sum of Squares Df Mean Square F Value p-value Prob> F  
Model 73.63 4 18.41 65.44 0.0030 Significant 
Conc. of methyl cellulose 3.78 1 3.78 13.44 0.0351  
Conc. of 
PEG400 
16.53 1 16.53 58.78 0.0046  
Conc. .of salt 0.78 1 0.78 2.78 0.1942  
Conc. of surfactant 52.53 1 52.53 186.78 0.0008  
Residual  0.84 3 0.28    
Cor Total 74.47 7     
The conc. of polymer, conc. of PEG and conc. of surfactant showed significant impact on gelling temperature. Thus, the reduced equation for gelling 
temp. can be represented as:  
&!!+ ,. =  .  –  . # ∗ .   ! !!"! 
+  . # ∗  .  $%& +  . 
∗ 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. 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(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  
Gelling temperature of the formulation increased with increase in 
the concentration of PEG400 and Conc. of surfactant. The conc. of 
surfactant was found to have greater impact on gelling temp. The 
negative sign of coefficient of polymer conc. indicates gelling temp. 
of the formulation decreased with increase in conc. of MC. 
Bioadhesion strength 
Bio adhesion strength was measured of all the formulation from F1 
to F8 and results of the bio adhesion strength are given in Table 6. 
Table 8 depicts the results of ANOVA rom the obtained data. 
Relationship between the independent variables and bioadhesion 
strength was generated using DOE software  
. − (/  *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P values of conc. of MC & conc. of surfactant were found to be <0.05, 
indicating that there is significant effect of conc. of polymer & 
surfactant on bio-adhesion strength. Thus, bio-adhesion strength can 
be expressed as 
. − (/  *+  
=  .  +  .  ∗ .  0) −  . 
∗ 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(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 
Bio-adhesion strength of the formulations were found to have 
increased with the increase in concentration of methyl cellulose and 
decreased with increase in conc. of surfactant. 
  
Table 8: ANOVA table of bio-adhesion strength 
Source Sum of Squares Df Mean Square F Value p-value Prob> F  
Model 14.96 4 3.74 21.70 0.0150 Significant 
Conc. of methyl cellulose 10.76 1 10.76 62.48 0.0042  
Conc. of PEG 400 0.64 1 0.64 3.71 0.1499  
Conc. of salt 0.068 1 0.068 0.40 0.5732  
Conc. of surfactant 3.48 1 3.48 20.23 0.0205  
Residual 0.52 3 0.17    
Cor Total 15.47 7     
 
Table 9: In vitro drug release profile of Batches F1 to F8 
Time (Hour) In-vitro diffusion study 
F1 F2 F3 F4 F5 F6 F7 F8 
0 0 0 0 0 0 0 0 0 
0.5 43.42 21.12 30.79 44.27 23.33 45.52 38.55 27.61 
1 64.91 43.16 47.32 69.32 39.41 62.29 61.28 43.69 
2 80.18 57.81 60.32 83.12 57.81 80.69 83.64 57.77 
3 96.20 68.16 76.16 97.69 68.16 97.20 94.20 72.34 
4  80.98 85.12  78.69   88.80 
5  94.23 92.18  85.82   95.14 
In vitro drug release for at 3 hours was taken as a parameter for comparison and results of ANOVA for the response are given in Table 10 using DOE 
software. 
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Table 10: ANOVA table for Response surface of In vitro drug release 
Source Sum of Squares df Mean Square F Value p-value Prob> F  
Model 1453.30 4 363.33 15.52 0.0241 Significant 
Conc. of methyl cellulose 1412.46 1 1412.46 60.35 0.0044  
Conc. of PEG 400 4.18 1 4.18 0.18 0.7012  
Conc. of salt 36.64 1 36.64 1.57 0.2996  
Conc. of surfactant  0.029 1 0.029 1.23 0.9742  
Residual 70.22 3 23.41    
Cor Total 1523.52 7     
Concentration of polymer, PEG & surfactant caused decrease in the release rate, as evident from the following equation 
 
In-Vitro drug release  
In vitro drug release of all the formulation was performed using 
saline phosphate buffer pH 7.4. Formulation F6 showed fastest In 
vitro release (97.2% in 3h) where as Formulation F5 followed 
slowest release pattern, releasing only 85.82% drug in 5h (Table 9). 
1 2* /*"+ *!(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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(( 
But, only conc. of polymer showed p<0.05, implying that only MC 
concentration significantly guides the In vitro drug release. As 
expected, the release rate decreased with increase in polymer 
concentration. Thus, the reduced equation become 
1 2* /*"+ *!(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Validation of optimization model 
The validation of the optimization model was carried out by 
preparing a checkpoint batch from the results of the overlay plot 
(Fig. 1) for the confirmation of the optimization of the formulation.  
 
Fig. 1: Overlay plot for formulation batches for validation of model 
 
The prepared checkpoint was further evaluated for all the responses 
for which equations have been generated. The experimental values 
of responses of the prepared checkpoint batch were near to the 
predicted values (Table 11) obtained from the overlay plot 
generated using 9.0. version of design expert software. Thus the 
model can be concluded as validated. 
 
Table 11: Characterization of check point (optimized) batch 
S. No. Responses Experimental value Predicted value 
1 Gelling temperature 38.0 °C 37.6 °C 
2 Bio adhesion strength 4.05 g/cm2 4.28g/cm2 
3 In vitro drug release 89.33 % 92% 
4. Viscosity cps 1389.50 cps 1411.12 cps 
 
Table 12: Release kinetics of optimized formulation 
Zero order release First order release Hixon Crowell Higuchi model Korsmeyer-Peppas model Release mechanism 
K0 R2 K1 R2 KHC R2 KH R2 N R2  Fickian diffusion 
9.34 0.961 0.076 0.905 0.284 0.869 25.19 0.970 0.244 0.892 
 
 
Fig. 2: In vitro diffusion and ex-vivo permeation profile of 
optimized batch 
 
According to the kinetic model fit analysis (Fig. 3), the formulation 
follows Higuchi model as it has highest R² value among the other 
models (Table 12).  
The ‘n’ value obtained from Korsemeyer-Peppas model was found 










In -vitro diffusion study 
X1 = A: conc of methyl cellulose
X2 = B: conc  of PEG
Actual Factors
C: conc of salt  = 3.49032
D: conc of surfactant  = 0.580032

























In -vitro diffusion study : 90.6569




In -vitro diffusion 92.3785
X1 0.710938
X2 9.14489
Bhadra et al. 




Fig. 3: Release kinetics study of optimized batch 
 
Ex-vivo permeation 
Exvivo permeation of the optimized batch was performed using 
Franz diffusion cell in saline phosphate buffer pH 7.4. The % 
Cumulative drug permeation was found to be 86.98% after 3 hours, 
which suggest similarity with the in-vitro release pattern (Fig. 2). 
In vivo study of the optimized batch 
In vivo study was carried out for confirming our concept that rectal 
administration of the prepared in-situ gel may improve 
bioavailability of celecoxib. For this, a comparative study was done 
between the prepared formulation & marketed formulation given by 
same route in same concentration. Spectrophotometric bioanalytical 
method was developed for analyzing celecoxib in plasma having 
linearity (r2= 0.992) within 0.5-1.0 mcg/ml. Results (Fig. 4, Table 13) 
showed that the AUC of celecoxib (370.63 µg/ml. hr) was found to be 
more than AUC of the marketed formulation (215.47 µg/ml. hr).  
 
 
Fig. 4: Comparative Plasma profile of in situ gel and marketed 
formulation 
 
Thus, a 1.54 folds increase in bioavailability could be achieved with 
the formulated in situ gel formulation in comparison with the 
marketed formulation. 
 
Table 13: Comparative in-vivo performance of formulation marketed formulation 
Formulation Cmax (µg/ml) Tmax (hour) AUC (µg/ml. hr) Fr (Relative bioavailability) 
In situ gel 244.05 3 370.63  
1.54 Marketed formulation 139.24 3 215.47 
 
CONCLUSION  
Development of the in situ gel for transmucosal delivery of celecoxib 
by rectal route was attempted for the increasing the bioavailability 
of drug. The optimized batch, containing methyl cellulose (0.72%), 
PEG400 (9.14%), NaCl (3.49%) and surfactant (0.51%), showed 
gelling temperature near to body temperature with adequate 
bioadhesion strength and In vitro drug release profile. In vivo study of the 
optimized batch in male Wistar rat showed both AUC and Cmax of the in 
situ gel was more than those of the marketed formulation, with 1.54 
folds increase in bioavailability by rectal route. Thus, the developed 
formulation can prove to be a better delivery option in critical pains. 
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